Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 16.09
OTCPK:NONOF's Cash to Debt is ranked lower than
55% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. OTCPK:NONOF: 16.09 )
Ranked among companies with meaningful Cash to Debt only.
OTCPK:NONOF' s 10-Year Cash to Debt Range
Min: 0.29  Med: 10.91 Max: N/A
Current: 16.09
Equity to Asset 0.48
OTCPK:NONOF's Equity to Asset is ranked lower than
72% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OTCPK:NONOF: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
OTCPK:NONOF' s 10-Year Equity to Asset Range
Min: 0.42  Med: 0.66 Max: 0.73
Current: 0.48
0.42
0.73
Interest Coverage 884.41
OTCPK:NONOF's Interest Coverage is ranked lower than
80% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OTCPK:NONOF: 884.41 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:NONOF' s 10-Year Interest Coverage Range
Min: 5.69  Med: 24.21 Max: 884.41
Current: 884.41
5.69
884.41
F-Score: 8
Z-Score: 17.68
M-Score: -2.76
WACC vs ROIC
13.05%
122.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 42.07
OTCPK:NONOF's Operating margin (%) is ranked higher than
95% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. OTCPK:NONOF: 42.07 )
Ranked among companies with meaningful Operating margin (%) only.
OTCPK:NONOF' s 10-Year Operating margin (%) Range
Min: 10.5  Med: 23.85 Max: 38.84
Current: 42.07
10.5
38.84
Net-margin (%) 31.53
OTCPK:NONOF's Net-margin (%) is ranked higher than
92% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. OTCPK:NONOF: 31.53 )
Ranked among companies with meaningful Net-margin (%) only.
OTCPK:NONOF' s 10-Year Net-margin (%) Range
Min: 11.39  Med: 17.53 Max: 30.13
Current: 31.53
11.39
30.13
ROE (%) 83.94
OTCPK:NONOF's ROE (%) is ranked higher than
98% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. OTCPK:NONOF: 83.94 )
Ranked among companies with meaningful ROE (%) only.
OTCPK:NONOF' s 10-Year ROE (%) Range
Min: 11.85  Med: 21.58 Max: 63.92
Current: 83.94
11.85
63.92
ROA (%) 42.14
OTCPK:NONOF's ROA (%) is ranked higher than
98% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. OTCPK:NONOF: 42.14 )
Ranked among companies with meaningful ROA (%) only.
OTCPK:NONOF' s 10-Year ROA (%) Range
Min: 8.5  Med: 14.78 Max: 37.03
Current: 42.14
8.5
37.03
ROC (Joel Greenblatt) (%) 179.22
OTCPK:NONOF's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. OTCPK:NONOF: 179.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OTCPK:NONOF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 17.66  Med: 35.52 Max: 140.48
Current: 179.22
17.66
140.48
Revenue Growth (3Y)(%) 13.20
OTCPK:NONOF's Revenue Growth (3Y)(%) is ranked higher than
70% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. OTCPK:NONOF: 13.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OTCPK:NONOF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -46.2  Med: 13.20 Max: 127.6
Current: 13.2
-46.2
127.6
EBITDA Growth (3Y)(%) 16.70
OTCPK:NONOF's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. OTCPK:NONOF: 16.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OTCPK:NONOF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -44.6  Med: 16.40 Max: 130.7
Current: 16.7
-44.6
130.7
EPS Growth (3Y)(%) 18.80
OTCPK:NONOF's EPS Growth (3Y)(%) is ranked higher than
76% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. OTCPK:NONOF: 18.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OTCPK:NONOF' s 10-Year EPS Growth (3Y)(%) Range
Min: 0.8  Med: 20.30 Max: 37.2
Current: 18.8
0.8
37.2
» OTCPK:NONOF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with OTCPK:NONOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 30.66
NONOF's P/E(ttm) is ranked higher than
56% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. NONOF: 30.66 )
Ranked among companies with meaningful P/E(ttm) only.
NONOF' s 10-Year P/E(ttm) Range
Min: 12.13  Med: 23.14 Max: 35.76
Current: 30.66
12.13
35.76
Forward P/E 22.94
NONOF's Forward P/E is ranked lower than
52% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. NONOF: 22.94 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.80
NONOF's PE(NRI) is ranked higher than
56% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 33.30 vs. NONOF: 30.80 )
Ranked among companies with meaningful PE(NRI) only.
NONOF' s 10-Year PE(NRI) Range
Min: 12.03  Med: 23.10 Max: 35.76
Current: 30.8
12.03
35.76
P/B 24.29
NONOF's P/B is ranked lower than
94% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. NONOF: 24.29 )
Ranked among companies with meaningful P/B only.
NONOF' s 10-Year P/B Range
Min: 3.52  Med: 6.78 Max: 31.9
Current: 24.29
3.52
31.9
P/S 9.61
NONOF's P/S is ranked higher than
52% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. NONOF: 9.61 )
Ranked among companies with meaningful P/S only.
NONOF' s 10-Year P/S Range
Min: 2.81  Med: 5.04 Max: 10.99
Current: 9.61
2.81
10.99
PFCF 30.91
NONOF's PFCF is ranked higher than
63% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 40.25 vs. NONOF: 30.91 )
Ranked among companies with meaningful PFCF only.
NONOF' s 10-Year PFCF Range
Min: 12.07  Med: 24.03 Max: 47.01
Current: 30.91
12.07
47.01
POCF 26.92
NONOF's POCF is ranked higher than
60% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. NONOF: 26.92 )
Ranked among companies with meaningful POCF only.
NONOF' s 10-Year POCF Range
Min: 9.91  Med: 18.24 Max: 32.48
Current: 26.92
9.91
32.48
EV-to-EBIT 22.52
NONOF's EV-to-EBIT is ranked higher than
60% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. NONOF: 22.52 )
Ranked among companies with meaningful EV-to-EBIT only.
NONOF' s 10-Year EV-to-EBIT Range
Min: 9.1  Med: 17.30 Max: 26.8
Current: 22.52
9.1
26.8
PEG 1.57
NONOF's PEG is ranked higher than
66% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 2.22 vs. NONOF: 1.57 )
Ranked among companies with meaningful PEG only.
NONOF' s 10-Year PEG Range
Min: 0.54  Med: 1.19 Max: 1.87
Current: 1.57
0.54
1.87
Shiller P/E 45.07
NONOF's Shiller P/E is ranked lower than
53% of the 112 Companies
in the Global Biotechnology industry.

( Industry Median: 44.71 vs. NONOF: 45.07 )
Ranked among companies with meaningful Shiller P/E only.
NONOF' s 10-Year Shiller P/E Range
Min: 18.94  Med: 31.93 Max: 50.95
Current: 45.07
18.94
50.95
Current Ratio 1.23
NONOF's Current Ratio is ranked lower than
85% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. NONOF: 1.23 )
Ranked among companies with meaningful Current Ratio only.
NONOF' s 10-Year Current Ratio Range
Min: 1.04  Med: 2.02 Max: 2.45
Current: 1.23
1.04
2.45
Quick Ratio 0.89
NONOF's Quick Ratio is ranked lower than
86% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. NONOF: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
NONOF' s 10-Year Quick Ratio Range
Min: 0.74  Med: 1.33 Max: 1.91
Current: 0.89
0.74
1.91
Days Inventory 281.51
NONOF's Days Inventory is ranked lower than
84% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. NONOF: 281.51 )
Ranked among companies with meaningful Days Inventory only.
NONOF' s 10-Year Days Inventory Range
Min: 201.98  Med: 304.77 Max: 417.53
Current: 281.51
201.98
417.53
Days Sales Outstanding 52.34
NONOF's Days Sales Outstanding is ranked higher than
60% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. NONOF: 52.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
NONOF' s 10-Year Days Sales Outstanding Range
Min: 45.09  Med: 52.94 Max: 152.61
Current: 52.34
45.09
152.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.34
NONOF's Dividend Yield is ranked higher than
55% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 1.28 vs. NONOF: 1.34 )
Ranked among companies with meaningful Dividend Yield only.
NONOF' s 10-Year Dividend Yield Range
Min: 0.79  Med: 1.51 Max: 2.47
Current: 1.34
0.79
2.47
Dividend Payout 0.42
NONOF's Dividend Payout is ranked lower than
61% of the 121 Companies
in the Global Biotechnology industry.

( Industry Median: 0.36 vs. NONOF: 0.42 )
Ranked among companies with meaningful Dividend Payout only.
NONOF' s 10-Year Dividend Payout Range
Min: 0.51  Med: 1.30 Max: 1.85
Current: 0.42
0.51
1.85
Dividend growth (3y) 46.20
NONOF's Dividend growth (3y) is ranked higher than
92% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 6.30 vs. NONOF: 46.20 )
Ranked among companies with meaningful Dividend growth (3y) only.
NONOF' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 22.70 Max: 49.4
Current: 46.2
0
49.4
Yield on cost (5-Year) 6.54
NONOF's Yield on cost (5-Year) is ranked higher than
92% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 1.26 vs. NONOF: 6.54 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NONOF' s 10-Year Yield on cost (5-Year) Range
Min: 3.74  Med: 7.16 Max: 11.7
Current: 6.54
3.74
11.7
Share Buyback Rate 2.60
NONOF's Share Buyback Rate is ranked higher than
97% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. NONOF: 2.60 )
Ranked among companies with meaningful Share Buyback Rate only.
NONOF' s 10-Year Share Buyback Rate Range
Min: 49.1  Med: 2.20 Max: -92.3
Current: 2.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 31.17
NONOF's Price/Tangible Book is ranked lower than
91% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. NONOF: 31.17 )
Ranked among companies with meaningful Price/Tangible Book only.
NONOF' s 10-Year Price/Tangible Book Range
Min: 3.14  Med: 6.16 Max: 31.53
Current: 31.17
3.14
31.53
Price/Projected FCF 4.62
NONOF's Price/Projected FCF is ranked lower than
53% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. NONOF: 4.62 )
Ranked among companies with meaningful Price/Projected FCF only.
NONOF' s 10-Year Price/Projected FCF Range
Min: 1.41  Med: 3.01 Max: 160.48
Current: 4.62
1.41
160.48
Price/DCF (Earnings Based) 1.08
NONOF's Price/DCF (Earnings Based) is ranked higher than
71% of the 14 Companies
in the Global Biotechnology industry.

( Industry Median: 1.18 vs. NONOF: 1.08 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 2.03
NONOF's Price/Median PS Value is ranked lower than
76% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. NONOF: 2.03 )
Ranked among companies with meaningful Price/Median PS Value only.
NONOF' s 10-Year Price/Median PS Value Range
Min: 0.15  Med: 0.87 Max: 2.07
Current: 2.03
0.15
2.07
Price/Peter Lynch Fair Value 1.44
NONOF's Price/Peter Lynch Fair Value is ranked higher than
69% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 1.61 vs. NONOF: 1.44 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
NONOF' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.07  Med: 0.97 Max: 1.55
Current: 1.44
0.07
1.55
Price/Graham Number 6.65
NONOF's Price/Graham Number is ranked lower than
73% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. NONOF: 6.65 )
Ranked among companies with meaningful Price/Graham Number only.
NONOF' s 10-Year Price/Graham Number Range
Min: 1.58  Med: 2.60 Max: 6.74
Current: 6.65
1.58
6.74
Earnings Yield (Greenblatt) (%) 4.42
NONOF's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. NONOF: 4.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NONOF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.7  Med: 5.80 Max: 11
Current: 4.42
3.7
11
Forward Rate of Return (Yacktman) (%) 25.67
NONOF's Forward Rate of Return (Yacktman) (%) is ranked higher than
72% of the 103 Companies
in the Global Biotechnology industry.

( Industry Median: 13.70 vs. NONOF: 25.67 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NONOF' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 1.7  Med: 22.00 Max: 35.6
Current: 25.67
1.7
35.6

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 19,749 20,912 21,976 24,386
EPS($) 2.37 2.81 2.95 3.32
EPS without NRI($) 2.37 2.81 2.95 3.32

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:NVO.USA, 0QIU.UK, NOVO B.Denmark, NOVA.Germany, NOVC.Germany, NOVOB.Switzerland,
Novo-Nordisk A/S is a healthcare company incorporated on November 28, 1931 in Denmark. The Company has diabetes product portfolios, including new generation insulins, a full portfolio of modern insulins as well as a human once-daily GLP-1 analog. In addition, it also has a position within haemophilia care, growth hormone therapy and hormone replacement therapy, and Company's first product to treat obesity, Saxenda, was approved in the United States in December 2014. The Company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. On December 23, 2014, the GLP-1 agonist liraglutide was approved in the United States in a 3 mg dose for weight management. The trade name for this product will be Saxenda and launch is planned for the first half of 2015. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy and hormone replacement therapy. In 2014 the Company announced that all activities within inflammation will be discontinued. The Company's insulin and other pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents with responsibility for specific geographical areas. The important markets are North America, China, Japan and the major European countries. In addition there is an increasing contribution to its total sales from key markets in the sales region International Operations such as Algeria, Turkey, Australia, India, Argentina, Brazil and Russia.
» More Articles for OTCPK:NONOF

Headlines

Articles On GuruFocus.com
Nintai Returns: Q2 2015 Jul 01 2015 
Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 
Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE May 03 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
Additional Changes to the Nintai Portfolio Apr 08 2015 
Probability and Magnitude in Investing Apr 02 2015 
Nintai Returns: Q1 2015 Apr 01 2015 
These High-Quality European Dividend Payers Could Benefit From A Rising Dollar Mar 18 2015 
To Reinvest or Not Reinvest: That is the Question Feb 19 2015 

More From Other Websites
Research and Markets: China Insulin Detemir (Novo Nordisk) Market Report 2010-2019 Sep 03 2015
Is Novo Nordisk (NVO) an Incredible Growth Stock? 3 Reasons Why It Will Be Tough to Beat Aug 31 2015
Now the work starts for Novo Nordisk in Clayton Aug 28 2015
Research and Markets: China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk Aug 28 2015
Novo Nordisk to Start PIONEER Program on Semaglutide Aug 27 2015
Novo Nordisk adding diabetes drug output in NC, Denmark Aug 26 2015
Novo Nordisk adding diabetes drug output in NC, Denmark Aug 26 2015
Nearly 700 N.C. jobs announced as part of $1.2B Novo Nordisk expansion Aug 26 2015
Novo May Benefit From Possible Shire-Baxalta Disruption Aug 14 2015
Biggest Insulin Maker May Build Next Diabetes Drug Plant in U.S. Aug 14 2015
Novo Nordisk's Net Income Up Y/Y, 2015 Outlook Maintained - Analyst Blog Aug 07 2015
We want to be seen as Chinese: Novo Nordisk Aug 06 2015
China gets tougher for Western drugmakers Aug 06 2015
China gets tougher for Western drugmakers Aug 06 2015
Research and Markets: Investigation Report on China's Liraglutide Market, 2011-2019 Featuring Novo... Aug 06 2015
AbbVie: Beware the Biosimilars? Jul 24 2015
Novo Nordisk says Flexpro PenMate gets FDA approval Jul 16 2015
Novo Nordisk Up on Positive Results from Diabetes Study - Analyst Blog Jul 13 2015
Novo Nordisk's new GLP-1 diabetes drug hits goal in trial Jul 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK